42 Percent of Transgender Women With Valid HIV Test Are HIV+
MONDAY, April 19, 2021 -- Forty-two percent of transgender women with a valid HIV test result have a positive result, with considerable regional and ethnic/racial variation, according to a report issued by the U.S. Centers for Disease Control and Prevention.
Taylor Robbins, M.P.H., from the CDC in Atlanta, and colleagues present data from 1,608 transgender women who participated in the National HIV Behavioral Surveillance (NHBS) in 2019 and early 2020, of whom 32 percent identified as a woman and 87 percent as a transgender woman.
The researchers found that 42 percent of the participants with a valid HIV test result tested positive for HIV. HIV prevalence varied by city, from 21 percent in Seattle to 58 percent in Atlanta. HIV prevalence varied by race and ethnicity and was 17 percent among Whites and among Native Hawaiian/other Pacific Islanders and 65 and 62 percent among American Indian/Alaska Natives and Black/African Americans, respectively. Of the participants, 17 percent had no health insurance and 7 percent had not visited a health care provider; 63 percent had household income at or below the poverty level. Forty-two percent of the participants had experienced homelessness in the 12 months before the interview and 17 percent had been incarcerated.
"These data provide a clear and compelling picture of the severe toll of HIV among transgender women and the social and economic factors -- including systemic racism and transphobia -- that are contributing to this unacceptable burden," Demetre Daskalakis, M.D., M.P.H., director of the CDC Division of HIV/AIDS Prevention, said in a statement.
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Read this next
FRIDAY, April 30, 2021 -- Life expectancy among people with HIV receiving antiretroviral therapy (ART) has significantly improved in Latin America and the Caribbean, according to...
FRIDAY, April 23, 2021 -- People living with HIV (PLWH) without known cardiovascular disease have an increased prevalence and volume of noncalcified coronary plaque, as measured...
MONDAY, April 19, 2021 -- Within two to four months of starting gender-affirming hormone therapy (GAHT), transfeminine adults have lower mean systolic blood pressure and...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.